About: Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid‐19
Creator	Zhang, Li Guo, Xin Liu, Miao Li, \| Meng, \| Daniel, \| Chai, Li Gao, Chong Leng, Yan Wu, \| Yang, Junyu You, Hua Chen, Xiao-Bing Chen, † \| Dai, Yuan Fen, \| Meng, † Tenen, G Yang, Jun-Hui Zhen, †
source	Medline; PMC
abstract	BACKGROUND: The management of critically ill patients with coronavirus disease 2019 (COVID‐19), caused by a new human virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is challenging. Recently, there have been several reports with inconsistent results after treatment with convalescent plasma (CP) on critically ill patients with COVID‐19, which was produced with a neutralizing antibody titer and tested in a P3 or P4 laboratory. However, due to the limitation of the conditions on mass production of plasma, most producers hardly had the capability to isolate the neutralizing antibody. Here, we report the clinical courses of three critically ill patients with COVID‐19 receiving CP treatments by total immunoglobulin G (IgG) titer collection. METHODS: Three patients with COVID‐19 in this study were laboratory confirmed to be positive for SARS‐CoV‐2, with radiographic and clinical features of pneumonia. CP was collected by total IgG titer of 160 (range, 200‐225 mL), and patients were transfused between 20 and 30 days after disease onset at the critical illness stage as a trial in addition to standard care. The clinical courses of these patients, including laboratory results and pulmonary functional and image studies after receiving convalescent plasma infusions, were reviewed. RESULTS: No therapeutic effect of CP was observed in any of the patients; instead, all three patients deteriorated and required extracorporeal membrane oxygenation treatment. A potential cytokine storm 4 hours after infusion of CP in Patient 2 was observed. No more patients were put on the trial of CP transfusion. CONCLUSIONS: We recommend extreme caution in using CP in critically ill patients more than 2 weeks after the onset of COVID‐19 pneumonia.
has issue date	2020-08-08(xsd:dateTime)
bibo:doi	10.1111/trf.15975
bibo:pmid	32770691
has license	no-cc
sha1sum (hex)	43ef1a14fd06148498bee85da47e10ae33b2591d
schema:url	https://doi.org/10.1111/trf.15975
resource representing a document's title	Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid‐19
has PubMed Central identifier	PMC7436937
has PubMed identifier	32770691
schema:publication	Transfusion
resource representing a document's body	covid:43ef1a14fd06148498bee85da47e10ae33b2591d#body_text
is schema:about of	named entity 'radiographic' named entity 'critically ill' named entity 'NEW' named entity 'DUE TO' named entity 'PATIENTS' named entity 'NEUTRALIZING ANTIBODY TITER' named entity 'ISOLATE' named entity 'TOTAL IMMUNOGLOBULIN G' named entity 'METHODS' named entity 'STUDY' named entity 'mass production' named entity 'patients' named entity 'management' named entity 'courses' named entity 'titer' named entity 'viral disease' named entity 'Convalescent plasma' named entity 'plasma' named entity 'IgG' named entity 'multiple organ failure' named entity 'fever' named entity 'COVID-19' named entity 'viral load' named entity 'IL-6' named entity 'titer' named entity 'Computed tomography' named entity 'intubated' named entity 'supportive care' named entity 'neutralizing antibody' named entity 'antibodies' named entity 'randomized controlled trial' named entity 'transfusion' named entity 'TRALI' named entity 'transfusion' named entity 'lungs' named entity 'infusion' named entity 'H1N1 2009' named entity 'radiographic' named entity 'pneumonia' named entity 'China' named entity 'pneumonia' named entity 'viral titers' named entity 'azotemia' named entity 'epidemic' named entity 'COVID' named entity 'institutional review board' named entity 'ecchymosis' named entity 'coronavirus disease 2019' named entity 'serum therapy' named entity 'coagulopathy' named entity 'COVID' named entity 'TNF-α' named entity 'convalescent plasma' named entity 'COVID' named entity 'viral infections' named entity 'transfusion' named entity 'lung' named entity 'produced' named entity 'study' named entity 'patients' named entity 'immunoglobulin' named entity 'neutralizing antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software